Sophiris Bio (NASDAQ:SPHS) has been assigned a $6.00 price target by research analysts at Maxim Group in a research report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price indicates a potential upside of 217.46% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Sophiris Bio in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Sophiris Bio has an average rating of “Buy” and an average target price of $6.25.

Shares of Sophiris Bio (NASDAQ SPHS) traded down $0.02 during midday trading on Monday, hitting $1.89. The stock had a trading volume of 154,300 shares, compared to its average volume of 277,600. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 1-year low of $1.80 and a 1-year high of $3.24.

An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. bought a new position in Sophiris Bio Inc (NASDAQ:SPHS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Maxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price Target” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/11/maxim-group-analysts-give-sophiris-bio-sphs-a-6-00-price-target.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.